Palo Alto, CA, United States of America

De Chao Yu


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **De Chao Yu: Innovator in Gene Therapy**

Introduction

De Chao Yu is a notable inventor based in Palo Alto, California, known for his contributions to the field of gene therapy. With a focus on developing innovative solutions through adenoviral vectors, his work has the potential to impact various medical applications significantly.

Latest Patents

Yu holds a patent titled "Adenovirus vectors containing cell status-specific response elements and methods of use thereof." This groundbreaking invention involves adenoviral vectors that include cell status-specific transcriptional regulatory elements, which provide targeted transcriptional regulation on an adenoviral gene. The concept of 'cell status' refers to a reversible physiological and/or environmental state, offering a flexible approach to gene therapy. The patent further encompasses compositions and host cells that incorporate these vectors, along with methods for utilizing them effectively.

Career Highlights

Yu is associated with Cold Genesys, Inc., where he has played a key role in advancing research and development in gene therapy. His work at the company is characterized by a commitment to leveraging innovative technologies to enhance therapeutic strategies.

Collaborations

During his career, De Chao Yu has collaborated with experts in the field, including his coworker Daniel R. Henderson. These collaborative efforts have likely fostered a rich environment for the development of pioneering approaches in genetic research and therapy.

Conclusion

In summary, De Chao Yu is an influential figure in the realm of gene therapy, with a patent that exemplifies his innovative spirit and dedication to improving medical technologies. His contributions through Cold Genesys, Inc. signify a promising advancement in the application of adenoviral vectors in therapeutic settings.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…